These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35874976)

  • 1. The Consistency Between the Chinese Essential Medicines List and Treatment Guidelines-Taking Oncology Medicines as an Example.
    Cheng L; Li C; Zhang X; Chen Y; Yan J
    Front Public Health; 2022; 10():943994. PubMed ID: 35874976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative comparison between the essential medicines for rheumatic diseases in children and young people in Africa and the WHO model list.
    Slamang W; Scott C; Foster HE
    Pediatr Rheumatol Online J; 2024 Jul; 22(1):63. PubMed ID: 38965620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
    Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
    ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of cytotoxic medicines in the WHO essential medicine list used in treating childhood malignancies in low-income and lower-middle-income countries: a systematic review protocol.
    Seneviwickrama M; Gunasekera S; Liyanage G; Heiyanthuduwa W; Jayakody S
    BMJ Open; 2023 Jun; 13(6):e071988. PubMed ID: 37336532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicines for cancers in children: The WHO model for selection of essential medicines.
    Robertson J; Magrini N; Barr R; Forte G; Ondari C
    Pediatr Blood Cancer; 2015 Oct; 62(10):1689-93. PubMed ID: 25929524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in updating national guidelines and essential medicines lists in Sub-Saharan African countries to include WHO-recommended postpartum hemorrhage medicines.
    Ng'ang'a J; Chitimbe T; Mburu R; Rushwan S; Ntirushwa D; Chinery L; Gülmezoglu AM
    Int J Gynaecol Obstet; 2022 Jun; 158 Suppl 1(Suppl 1):11-13. PubMed ID: 35762803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawn medicines included in the essential medicines lists of 136 countries.
    Charles O; Onakpoya I; Benipal S; Woods H; Bali A; Aronson JK; Heneghan C; Persaud N
    PLoS One; 2019; 14(12):e0225429. PubMed ID: 31791048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases.
    Kishore SP; Blank E; Heller DJ; Patel A; Peters A; Price M; Vidula M; Fuster V; Onuma O; Huffman MD; Vedanthan R
    J Am Coll Cardiol; 2018 Feb; 71(5):564-574. PubMed ID: 29406862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.
    Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N
    Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
    Chivukula MV; Tisocki K
    WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO.
    Piggott T; Nowak A; Brignardello-Petersen R; Cooke GS; Huttner B; Schünemann HJ; Persaud N; Magrini N; Moja L
    BMJ Open; 2022 Feb; 12(2):e053349. PubMed ID: 35144950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the Essential Medicines List, Standard Treatment Guidelines and prescribing restrictions, as an integrated strategy to enhance quality, efficacy and safety of and improve access to essential medicines in Papua New Guinea.
    Joshua IB; Passmore PR; Sunderland BV
    Health Policy Plan; 2016 May; 31(4):538-46. PubMed ID: 26378052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.
    Jenei K; Aziz Z; Booth C; Cappello B; Ceppi F; de Vries EGE; Fojo A; Gyawali B; Ilbawi A; Lombe D; Sengar M; Sullivan R; Trapani D; Huttner BD; Moja L
    Lancet Glob Health; 2022 Dec; 10(12):e1860-e1866. PubMed ID: 36183737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selection and use of essential medicines. Report of the WHO expert committee, 2005 (including the 14th model list of essential medicines).
    World Health Organ Tech Rep Ser; 2006; (933):1-119, back cover. PubMed ID: 17566509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selection and use of essential medicines.
    World Health Organization
    World Health Organ Tech Rep Ser; 2011; (965):i-xiv, 1-249. PubMed ID: 22891532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Selection and Use of Essential Medicines.
    World Health Organ Tech Rep Ser; 2015; (994):vii-xv, 1-546. PubMed ID: 27183787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study.
    Piggott T; Moja L; Akl EA; Lavis JN; Cooke G; Kredo T; Hogerzeil HV; Huttner B; Alonso-Coello P; Schünemann H
    J Clin Epidemiol; 2023 Feb; 154():146-155. PubMed ID: 36584732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys.
    Holloway KA; Henry D
    PLoS Med; 2014 Sep; 11(9):e1001724. PubMed ID: 25226527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interpretation of China national essential medicines list 2018.
    Zuo W; Mei D; Sun W; Tang X; Niu Z; Gao D; Zhang B
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):191-200. PubMed ID: 31914825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.